Treatment of Nonalcoholic Fatty Liver Disease with Total Alkaloids in Rubus aleaefolius Poir through Regulation of Fat Metabolism

被引:10
|
作者
Li, Ying [1 ,2 ]
Zhao, Jinyan [3 ,4 ]
Zheng, Haiyin [5 ]
Zhong, Xiaoyong [3 ,4 ]
Zhou, Jianheng [5 ]
Hong, Zhenfeng [3 ,4 ]
机构
[1] Xiamen Hosp Tradit Chinese Med, Xiamen 361009, Fujian, Peoples R China
[2] Jinshan St Community Hlth Serv, Xiamen 361000, Fujian, Peoples R China
[3] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou 350122, Fujian, Peoples R China
[4] Fujian Univ Tradit Chinese Med, Fujian Key Lab Integrat Med Geriatr, Fuzhou 350122, Fujian, Peoples R China
[5] Dept Integrat Med, Fuzhou 350122, Fujian, Peoples R China
关键词
MALONYL-COA; INSULIN-RESISTANCE; HEPATIC STEATOSIS; RISK-FACTORS; STEATOHEPATITIS; PREVALENCE; KINASE; MICE;
D O I
10.1155/2014/768540
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Total alkaloids in Rubus aleaefolius Poir (TARAP) is a folk medicinal herb that has been used clinically in China to treat nonalcoholic fatty liver disease (NAFLD) for many years. However, the mechanism of its anti-NAFLD effect is largely unknown. In this study, we developed a NAFLD rat model by supplying a modified high-fat diet (mHFD) ad libitum for 8 weeks and evaluated the therapeutic effect of TARAP in NAFLD rats as well as the underlying molecular mechanism. We found that TARAP could reduce the serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein (LDL-C) levels and increase the serum high-density lipoprotein (HDL-C) level in NAFLD rats. In addition, TARAP treatment reduced expression of fatty acid synthetase (FAS), and acetyl-CoA carboxylase (ACC) and upregulated the expression of carnitine palmitoyltransferase (CPT). Our results suggest that regulation of lipid metabolism may be a mechanism by which TARAP treats NAFLD.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
    Pei, Ke
    Gui, Ting
    Kan, Dongfang
    Feng, Huichao
    Jin, Yanqiang
    Yang, Ying
    Zhang, Qian
    Du, Ziwei
    Gai, Zhibo
    Wu, Jibiao
    Li, Yunlun
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [22] Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
    Cohen, David E.
    Fisher, Edward A.
    SEMINARS IN LIVER DISEASE, 2013, 33 (04) : 380 - 388
  • [23] IRON METABOLISM IN CHILDREN WITH NONALCOHOLIC FATTY LIVER DISEASE
    Flisiak-Jackiewicz, M.
    Klusek-Oksiuta, M.
    Tarasow, E.
    Koc-Zorawska, E.
    Wojtkowska, M.
    Lebensztejn, D.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S747 - S747
  • [24] Drug metabolism alterations in nonalcoholic fatty liver disease
    Merrell, Matthew D.
    Cherrington, Nathan J.
    DRUG METABOLISM REVIEWS, 2011, 43 (03) : 317 - 334
  • [25] Heterogeneity of phosphatidylcholine metabolism in nonalcoholic fatty liver disease
    Qadri, Sami
    Blom, Sami
    Pitkanen, Kari
    Ahlholm, Noora
    Porthan, Kimmo
    Luukkonen, Panu K.
    Juuti, Anne
    Sammalkorpi, Henna
    Penttila, Anne
    Arola, Johanna
    Oresic, Matej
    Hyotylainen, Tuulia
    Yki-Jarvinen, Hannele
    JOURNAL OF HEPATOLOGY, 2022, 77 : S111 - S111
  • [26] Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma
    Zhao, Jinyan
    Lin, Wei
    Cao, Zhiyun
    Liu, Liya
    Zhuang, Qunchuan
    Zhong, Xiaoyong
    Hong, Zhenfeng
    Peng, Jun
    ONCOLOGY REPORTS, 2013, 30 (03) : 1309 - 1314
  • [27] Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
    Shrestha, Rupesh
    Sudhamshu, K. C.
    Thapa, Pukar
    Pokharel, Arbinda
    Karki, Niyanta
    Jaishi, Bikash
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (07)
  • [28] Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Hung, Chun Kit
    Bodenheimer, Henry C., Jr.
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 175 - +
  • [29] Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Golabi, Pegah
    Bush, Haley
    Younossi, Zobair M.
    CLINICS IN LIVER DISEASE, 2017, 21 (04) : 739 - 753
  • [30] Current treatment for nonalcoholic fatty liver disease
    Katsiki, Niki
    Athyros, Vasilios G.
    Karagiannis, Asterios
    Mikhailidis, Dimitri P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (13) : 2141 - 2142